Growth capital Velentium Medical has recently attracted significant growth capital from 1315 Capital with strategic expansion plans in commercial manufacturing, product development, regulatory capabilities, automation, and infrastructure. This signals readiness for scaled partnerships and vendor integration to meet increasing demand.

Expansion readiness With a 51-200 employee base and ongoing investments to expand manufacturing and regulatory capabilities, Velentium is positioned to onboard larger programs and complex projects, offering a pathway for tiered collaboration with mid to large medical device manufacturers.

Cybersecurity emphasis The company emphasizes cybersecurity training and has launched online courses for medical device developers, indicating a proactive stance on secure development and potential opportunities to provide advanced security solutions, audits, and turnkey compliance support.

Executive leadership A recent leadership shift to a new CEO coupled with continued growth funding suggests a strategic pivot and appetite for high-impact programs, making Velentium a compelling candidate for partnerships in early-stage to scale-up projects.

Medical device focus Specialization in active implantables, neuromodulation, and neuromodulatory devices, along with Class II wearable and Class III implantables, aligns Velentium with high-complexity, high-margin opportunities and a portfolio fit for tier-one device developers seeking turnkey design-to-manufacture support.